The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Dealing

24 Apr 2018 17:04

RNS Number : 9918L
Omega Diagnostics Group PLC
24 April 2018
 

 

Omega Diagnostics Group PLC

("Omega" or the "Company")

 

PDMR Dealing

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it was notified on 24 April 2018 that Edward Valente, Group R&D Director of the Company has purchased 124,044 ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") at a price of 14.5 pence per Ordinary Share.

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Edward Valente

2.

Reason for notification

b)

Position / status

Group R&D Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Purchase of Ordinary Shares

 GB00B1VCP282

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Volume(s)

Price(s) £

124,044

0.145

 

d)

Aggregated information

Aggregated volume Price

Aggregate Volume(s)

Volume weighted average Price) £

124,044

0.145

 

e)

Date of the transaction

24/04/18

f)

Place of the transaction

LSE

 

Contacts:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Colin King, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

Jag Grewal, Group Sales and Marketing Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)

 

Camille Gochez (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKQDKABKDBQB
Date   Source Headline
16th Sep 202211:13 amRNSPurchase of Shares by Directors
13th Sep 20227:00 amRNSInvestor presentation and Confirmation of AGM
12th Sep 20227:00 amRNSFinal Results
2nd Sep 202210:15 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSChange of preliminary results date
12th Aug 20227:00 amRNSChange of preliminary results date
8th Aug 20227:00 amRNSConfirmation of Preliminary Results
5th Aug 202212:09 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSCompletion of Sale of the CD4 Business
11th Jul 20227:00 amRNSPayment received
4th Jul 20227:00 amRNSHeads of Terms agreed for Sale of CD4 Business
23rd Jun 20223:13 pmRNSHolding(s) in Company
10th Jun 20227:00 amRNSGrant of share incentive awards
8th Jun 20221:47 pmRNSPDMR/Director Dealing
6th Jun 20222:29 pmRNSResult of General Meeting and Total Voting Rights
1st Jun 20227:00 amRNSResult of Open Offer
13th May 202210:05 amRNSPosting of Circular and Notice of General Meeting
11th May 20223:28 pmRNSHolding(s) in Company
6th May 20227:01 amRNSInvestor presentation
6th May 20227:00 amRNSPlacing, Subscription and Open Offer
7th Apr 20227:00 amRNSTrading Update
11th Mar 20227:00 amRNSUpdate on validation under CTDA legislation
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn
7th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20223:40 pmRNSResult of General Meeting
7th Mar 202211:03 amRNSConfirmation of Sale of Alva business
1st Mar 20227:00 amRNSResult of Open Offer
18th Feb 20227:00 amRNSInvestor Meeting
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
11th Feb 202211:05 amRNSSecond Price Monitoring Extn
11th Feb 202211:00 amRNSPrice Monitoring Extension
11th Feb 20227:01 amRNSFundraising to raise gross proceeds of up to £7m
11th Feb 20227:00 amRNSSale of Alva manufacturing business
10th Feb 20222:06 pmRNSSecond Price Monitoring Extn
10th Feb 20222:00 pmRNSPrice Monitoring Extension
10th Feb 20221:33 pmRNSSpeculation regarding a potential fundraise
8th Feb 20224:41 pmRNSSecond Price Monitoring Extn
8th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSCE-Mark for self-test for VISITECT® COVID-19 test
2nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSSpeculation regarding a potential fundraise
19th Jan 20227:00 amRNSDirectorate Change
10th Jan 20223:20 pmRNSConfirmation of detection of Omicron variant
4th Jan 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.